N-dodecyl-N-methyl-hydroxylamine | 117356-59-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-dodecyl-N-methyl-hydroxylamine
• 英文别名: N-Dodecyl-N-methyl-hydroxylamin；N-dodecyl-N-methylhydroxylamine
• CAS: 117356-59-9
• 化学式: C₁₃H₂₉NO
• 分子量: 215.379
• InChiKey: WWRMRGSSMGHJPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  15
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-十二烷基甲胺 在 乙醇 、 双氧水 作用下， 生成 N-dodecyl-N-methyl-hydroxylamine
  参考文献：
  名称：

  Process of producing assistants in the textile and related industries

  摘要：

  公开号：

  US02169976A1

文献信息

• Design and Synthesis of 5-Lipoxygenase Inhibitors
  作者：Michael Strasser、Philip Cooper、Beatrice Dewald、Trevor Payne

  DOI：10.1002/hlca.19880710528

  日期：1988.8.10

  substrate specificity for 5-lipoxygenase and the known stereochemical course of the reaction, a hypothetical model of the enzyme active site was developed and used to design 2 types of selective inhibitors of 5-lipoxygenase. Both inhibitor types used aromatic rings in place of (Z)-olefins of the substrate and were designed to mimic the nonpolar end of arachidonic acid. One inhibitor type used a carboxylic-acid

  基于对5-脂氧合酶的底物特异性和已知的反应立体化学过程，开发了酶活性位点的假设模型，并用于设计两种类型的5-脂氧合酶的选择性抑制剂。两种抑制剂类型均使用芳族环代替底物的（Z）-烯烃，并被设计为模拟花生四烯酸的非极性末端。一种抑制剂类型与已知的环氧合酶抑制剂类似，使用羧酸与酶的O结合中心相互作用，而另一种抑制剂则采用羟胺功能与预计在酶活性位点的酪氨酸或半胱氨酸自由基相互作用。 。选择性5-脂氧合酶抑制剂是7-（己氧基）萘-2-乙酸（1）和N-甲基；-N（7-丙氧基萘-2-乙基）羟胺（2）。讨论了两种抑制剂的构效关系。
• DE664425
  申请人：——

  公开号：——

  公开（公告）日：——
• Method of Modulating Protein 14-3-3 Functionality By Facilitating or Inhibiting Phosphorylation
  申请人：Woodcock Joanna

  公开号：US20130231305A1

  公开（公告）日：2013-09-05

  The present invention relates to a method of modulating cellular activity. More particularly, the present invention provides a method of modulating apoptosis by modulating protein 14-3-3 phosphorylation and, thereby its functionality. The present invention still further extends to methods for identifying agents capable of modulating protein 14-3-3 phosphorylation. The method and molecules of the present invention are useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted cellular activity, such as unwanted cell survival.
• Reagents For HCV Antigen-Antibody Combination Assays
  申请人：ORTHO-CLINICAL DIAGNOSTICS, INC.

  公开号：US20160109447A1

  公开（公告）日：2016-04-21

  The present invention is directed to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a sample. The combination immunoassays of the present invention employ a non-ionic detergent that effectively exposes or releases the HCV core antigen from virions in a sample without interfering with the performance of other reagents such as the capture of anti-HCV antibodies by recombinant HCV antigens.